University of Texas Rio Grande Valley

ScholarWorks @ UTRGV
Health and Biomedical Sciences Faculty
Publications and Presentations

College of Health Professions

1-2018

Analysis of PTPRK polymorphisms in association with risk and
age at onset of Alzheimer’s disease, cancer risk, and cholesterol
Yang Chen
Chun Xu
The University of Texas Rio Grande Valley

Sam Harirforoosh
Xingguang Luo
Ke-Sheng Wang
East Tennessee State University

Follow this and additional works at: https://scholarworks.utrgv.edu/hbs_fac
Part of the Psychiatry and Psychology Commons

Recommended Citation
Chen, Y., Xu, C., Harirforoosh, S., Luo, X., & Wang, K. S. (2018). Analysis of PTPRK polymorphisms in
association with risk and age at onset of Alzheimer's disease, cancer risk, and cholesterol. Journal of
psychiatric research, 96, 65–72. https://doi.org/10.1016/j.jpsychires.2017.09.021

This Article is brought to you for free and open access by the College of Health Professions at ScholarWorks @
UTRGV. It has been accepted for inclusion in Health and Biomedical Sciences Faculty Publications and
Presentations by an authorized administrator of ScholarWorks @ UTRGV. For more information, please contact
justin.white@utrgv.edu, william.flores01@utrgv.edu.

HHS Public Access
Author manuscript
Author Manuscript

J Psychiatr Res. Author manuscript; available in PMC 2018 October 20.
Published in final edited form as:
J Psychiatr Res. 2018 January ; 96: 65–72. doi:10.1016/j.jpsychires.2017.09.021.

Analysis of PTPRK polymorphisms in association with risk and
age at onset of Alzheimer’s disease, cancer risk, and cholesterol
Yang Chen1, Chun Xu2, Sam Harirforoosh3, Xingguang Luo4,5,*, and Ke-Sheng Wang1,5,*
1Department

of Biostatistics and Epidemiology, College of Public Health, East Tennessee State
University, Johnson City, TN 37614, USA

Author Manuscript

2Department

of Health and Biomedical Sciences, College of Health Affairs, University of Texas
Rio Grande Valley, Brownsville, TX 78520, USA
3Department

of Pharmaceutical Sciences, Gatton College of Pharmacy, ETSU, East Tennessee
State University, Johnson City, TN 37614, USA

4Department
5Biological

of Psychiatry, Yale University School of Medicine, New Haven, CT 06516, USA

Psychiatry Research Center, Huilongguan Hospital, Beijing, China

Abstract
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The human receptor-type protein-tyrosine phosphatase kappa (PTPRK) gene is highly expressed in
human brain and is previously associated with neuropsychiatric disorders and cancer. This study
investigated the association of 52 single nucleotide polymorphisms (SNPs) in the PTPRK with the
risk and age at onset (AAO) of Alzheimer’s disease (AD) in 791 AD patients and 782 controls.
Five SNPs (top SNP rs4895829 with p=0.0125) were associated with the risk of AD based on a
multiple logistic regression (p<0.05); while 6 SNPs (top SNP rs1891150 with p=8.02×10−6) were
associated with AAO by using a multiple linear regression analysis. Interestingly, rs2326681 was
associated with both the risk and AAO of AD (p=4.65×10−2 and 5.18×10−3, respectively). In a
replication study, the results from family-based association test - generalized estimating equation
(GEE) statistics and Wilcoxon test showed that seven SNPs were associated with the risk of AD
(top SNP rs11756545 with p=1.02×10−2) and 12 SNPs were associated with the AAO (top SNP
rs11966128 with p=1.39×10−4), respectively. One additional sample showed that four SNPs were
associated with risk of cancer (top SNP rs1339197 with p=4.1×10−3), 12 SNPs associated with
LDL-cholesterol (top SNP rs4544930 with p=3.47×10−3), and 8 SNPs associated with total
cholesterol (top SNP rs1012049 with p=6.09×10−3). In addition, the AD associated rs4895829 was
associated with the gene expression level in the cerebellum (p=7.3×10−5). The present study is the
first study providing evidence of several genetic variants within the PTPRK gene associated with
the risk and AAO of AD, risk of cancer, LDL and total cholesterol levels.
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Alzheimer’s disease (AD), as the most common type of dementia, is a chronic
neurodegenerative disease that slowly destroys memory and thinking skills (Burns and Iliffe,
2009). The irreversible and progressive course of disease possibility leads to loss of the
ability to carry out the simplest tasks (Querfurth and LaFerla, 2010). In 2013, approximately
5 million Americans aged 65 years or older were living with AD; while this number is
projected to rise to 13.8 million, a nearly three-fold increase, by 2050 (Hebert et al., 2013).
In 2010, the costs associated with AD were projected to fall between $159 and $215 billion;
whereas these costs are estimated to be between $379 and more than $500 billion annually
by 2040 (Hurd et al., 2013). Worldwide, the number of individuals living with AD was 26.6
million in 2006 and this number will quadruple and 1 in 85 persons worldwide will be living
with the disease by 2050 (Brookmeyer et al., 2007). The genetic heritability of AD ranges
from 49% to 79% based on reviews of twin and family studies (Gatz et al., 2006). Age at
onset (AAO) is also genetically controlled. Previous studies showed that the estimated
heritability of 42% for AAO of AD and 57–78% of the variance of AAO was related to
genetic effects (Daw et al., 2000; Pedersen et al., 2001; Li et al., 2002).
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With advances of technology developed, a number of genes have been suggested to be
associated with AD. In the current study, we are interested in human receptor-type proteintyrosine phosphatase kappa (PTPRK) gene, which is located at 6q22.2-q22.3 (Zhang et al.,
1998). The protein encoded by this gene is a member of the protein tyrosine phosphatase
(PTP) family. PTPs are known to be signaling molecules that regulate a variety of cellular
processes including cell growth, differentiation, mitotic cycle, and oncogenic transformation
(Yang et al., 1997). PTPRK is expressed in a number of tissues such as brain, spleen,
prostate, and ovary. Some studies showed that PTPRK may play a role in the regulation of
processes involving cell contact and adhesion (Fuchs et al., 1996). Previous genetic studies
have shown that several single nucleotide polymorphisms (SNPs) such as rs17461290 and
rs11753871within the PTPRK gene are associated with three adult psychiatric disorders:
schizophrenia, major depressive disorder, and bipolar disorder (Hamshere et al., 2009;
Network and Pathway Analysis Subgroup of Psychiatric Genomics Consortium et al., 2015).
It has been found that there is a significant relationship between the presence of PTPRK
mutations and short malignant glioma patient survival time (Assem et al., 2012). Another
study suggested that there was an association between Alzheimer’s disease prevalence and
malignant brain tumor incidence (Lehrer, 2010). In addition, it has been demonstrated that
the PTPRK gene is a potential deletion target in primary central nervous system lymphomas
that can present as progressive dementia (Nakamura et al., 2003). Increasing evidence
suggests that total cholesterol levels are associated with AD and cognitive impairment
(Ahmed et al., 2014; Giudetti et al., 2016). Thus, we hypothesize that the PRPTK genetic
variants may play a role in cholesterol metabolism.
However, no study has focused on the relationship between of PTPRK gene and AD,
especially AAO of AD. This study aimed to investigate the association of PTPRK gene with
the risk and AAO of AD by using a case-control sample, followed by a replication using a
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family-based study design. In addition, a third sample was used to examine the associations
with risk of cancer, LDL- and total cholesterol levels.

2.
2.1.

Materials and Methods
Subjects

Author Manuscript

2.1.1. GenADA case-control study—Eight hundred and six patients with AD and 782
controls with complete genotype and phenotype information in a Canadian sample (Table 1)
were selected from the Multi-Site Collaborative Study for Genotype-Phenotype Associations
in Alzheimer’s disease and the Neuroimaging component of Genotype-Phenotype
Associations in Alzheimer’s disease (GenADA) - Study Accession: phs000219.v1.p1. The
details of these subjects were described elsewhere (Li et al., 2008; Filippini et al., 2009).
Genotyping was conducted using the Affymetrix technique. There were 52 SNPs within the
PTPRK gene.
2.1.2. NIA-LOAD family study—In total, 3007 individuals were available from the
National Institute on Aging - Late Onset Alzheimer’s Disease (NIA-LOAD) Family Study:
Genome-Wide Association Study for Susceptibility Loci – Study Accession:
phs000168.v1.p1. The details about these subjects were described elsewhere (Lee et al.,
2008). Genotyping was conducted by the Center for Inherited Disease Research (CIDR)
using the Illumina Infinium II assay protocol. Totally, 1266 AD cases and 1279 non-AD
individuals (including 1070 with AAO values) from 1386 pedigree (589 nuclear families)
(Table 1) were included in this study. There were 88 SNPs within the PTPRK gene.
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2.1.3. The Marshfield sample—The Marshfield sample is from the publicly available
data in A Genome-Wide Association Study on Cataract and HDL in the Personalized
Medicine Research Project Cohort - Study Accession: phs000170.v1.p1 (dbGaP). The
details about these subjects were described elsewhere (McCarty et al., 2005, 2008). Cancer
cases were defined as any diagnosed cancer excluding minor skin cancer; while age at onset
of cancer was defined by date of the earliest cancer diagnosis in the registry. Genotyping
data using the ILLUMINA technique are available for 3564 Caucasian individuals (716
cancer cases and 2848 controls). Adjusted (age 59, BMI 29, no estrogen) baseline LDL
values (mean ± SD = 149.1±26.9) and total cholesterol level (mean ± SD = 216.2±28.1)
available for 2273 individuals were treated as continuous variables. Within the PTPRK gene,
79 SNPs were available.
2.2.

Statistical methods

Author Manuscript

2.2.1. Genotype quality control—Hardy-Weinberg equilibrium (HWE) was tested
using Golden Helix Software (http://www.goldenhelix.com/SNP_Variation/HelixTree/
index.html). To deal with population stratification, the principal component analysis
approach (Price et al., 2006) in Golden Helix was used to identify outlier individuals for the
case-control data. Then, minor allele frequency (MAF) was determined for each SNP using
HAPLOVIEW software (Barrett et al., 2005).
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2.2.2. Multiple logistic regression models in PLINK software—For the casecontrol designs, the multiple logistic regression analyses of risk of AD and cancer as binary
traits, adjusted for age and sex, were performed. The asymptotic p-values for the logistic
regression models were observed while the odds ratio (OR) and its 95% confident interval
(CI) were estimated using PLINK v1.07 (Purcell et al., 2007). Multiple linear regression
analysis was used to examine the associations of SNPs with AAO of AD in the GenADA
Canadian sample and the LDL and total cholesterol in the Marshfield sample after adjusting
for age and sex. The asymptotic p-values were observed. The OR and its standard error for
the logistic models, and the regression coefficient (β) for the linear models, were estimated
using PLINK v1.07. To deal with multiple testing, Bonferroni correction
(α=0.05/52=9.62×10−4) for the discovery in the Marshfield sample was used for statistical
significance.
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2.2.3. Family-based association study—A family-based association analysis for AD
was performed using PBAT version 36.1 (Van Steen et al., 2005). The advantages of using a
family based association include that the design accommodates nuclear families with
missing parental genotypes, extended pedigrees with missing genotypic information and
contains analysis of SNPs, haplotype analysis, quantitative traits, and time to onset
phenotypes. For the affection status of AD, the family‐based association test - generalized
estimating equation (FBAT-GEE) statistic was used to perform family-based association
analysis (Lange et al., 2003). For testing time-to-onset trait (AAO), FBAT-Wilcoxon
statistics were employed (Lange et al., 2004). The AAO values for healthy siblings were
censored and age at entry into the study was used.
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2.2.4. In silico analysis—We evaluated potential function of the disease associated
SNP. First, we examined if these variants were located within the regions of the gene that
might have potential functional importance. The sequences containing the associated SNPs
were examined for microRNA binding sites, splicing sites, regulatory gene regions, and
species-conserved regions using NIH-SNP Function Prediction (http://snpinfo.niehs.nih.gov/
cgi-bin/snpinfo/snpfunc.cgi). Second, to determine if disease associated SNPs with PRPRK
expression levels in human brain, we used publicly available data from the Genotype-Tissue
Expression (GTEx) project (GTEx Consortium et al., 2015), in which, there is RNA
sequencing on brain tissue from healthy donors available, resulting in genotype and
expression phenotype data for ~100–120 normal individuals in multiple different brain
regions. The information about subjects and RNA quality can be found in the GTEx website
(www.gtexportal.org).
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3.
3.1.

Results
Descriptive statistics
Based on the principal components analysis using the Golden Helix and missing values of
AAO, we removed 15 individuals from the GenADA-case control sample. Consequently,
791 AD cases and 782 controls were left for further analysis from the Canadian sample
(GenADA). The demographic characteristics of the subjects in these three samples are
shown in the Table 1. The mean AAO for AD cases was 76.4 and 72.3 years in the NIA
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sample and Canadian samples, respectively. The mean age at entry was 75.5 years for
controls in NIA sample, and was 77.6 years in AD cases versus 73.4 years in controls in the
Canadian sample. The mean age at entry was 71.1 years in cancer cases versus 65.1 years in
controls in the Marshfield sample.
3.2.

Case-control association analyses in the GenADA Canadian sample

Author Manuscript

Single marker analysis showed that five SNPs were associated with risk and six SNPs were
associated with AAO (p<0.05) (Table 2). The strongest association was observed between
SNP rs4895829 and risk of AD (OR=0.65, 95%CI=0.47–0.91, p=1.25×10−2). The top two
SNPs showing significant associations with AAO were rs1891150 and rs1341597
(p=8.02×10−6 and 8.33×10−5, respectively), remained significant after a Bonferroni
correction (p<9.62×10−4). Interestingly, rs2326681 was associated with both the risk and
AAO of AD (p=4.65×10−2 and 5.18×10−3, respectively). Fig.1 shows the location of the
SNPs showing association with AD and/or AAO.
3.3.

Family-based association analyses with the NIA-LOAD data
Seven SNPs were associated with AD (p<0.05) by using FBAT-GEE analysis for affection
status in the family-based study (Table 3). The most significantly associated SNP was
rs1016015 (p=2.3×10−2) in an additive model and rs11756545 (p=1.02×10−2) in a dominant
model. Our results further showed 12 SNPs associated with AAO (p<0.05) by using the
FBAT-Wilcoxon test (Table 4). The most significantly AAO associated SNP was rs11966128
(p=1.39×10−4) in an additive model which remained significant after a Bonferroni correction
(p<0.05/88=5.68×10−4). In addition, rs7748155 was associated with both the risk and AAO
of AD in the family sample (p=1.57×10−2 and 2.07×10−2, respectively).

Author Manuscript

3.4.
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3.5.

Associations with cancer and cholesterol in the Marshfield sample
Table 5 showed that four SNPs were associated with the risk of cancer (top SNP rs1339197
with OR=0.84, 95%CI=0.74–0.95, p=4.1×10−3). We identified 12 SNPs associated with
LDL-cholesterol and 8 SNPs associated with total cholesterol (p<0.05) in the Marshfield
sample (Table 5). The first three most significant SNPs for LDL-cholesterol were
rs4544930, rs1012049 and rs9372885 (p = 3.47×10−3, 5.31×10−3 and 6.6×10−3,
respectively). The top two SNPs associated with total cholesterol were rs1012049 and
rs17352289 (p=6.09×10−3 and 8.87×10−3, respectively). Interestingly, rs7767531 was
associated with cancer, LDL-cholesterol and total cholesterol (p=4.12×10−2, 3.26×10−2,
1.4×10−2, respectively); while four SNPs (rs7767531, rs4533930, rs1012049 and
rs17352289) were associated with both LDL-cholesterol and total cholesterol levels.
In silico analysis
To test if the sequences containing the associated SNPs were located at microRNA binding
sites, splicing sites, regulatory gene regions, and species-conserved regions using NIH-SNP
Function Prediction (http://snpinfo.niehs.nih.gov/cgi-bin/snpinfo/snpfunc.cgi). We found
SNP rs7748155 associated with both AD and AAO and was located at the gene regulatory
region and species-conserved region; while AAO-associated SNPs (rs17055612 and
rs17055719) were located at the gene regulatory regions. The cholesterol associated SNP
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rs17828130 was a coding nonsynonymous SNP and was located at the gene regulatory
region; while rs9372885 was located at the gene regulatory region.
Having established strong associations of disease associated SNPs with AAO and risk of
AD, we tested if the genotype at these SNPs are associated with levels of gene expression in
the brain, based on the date from The Genotype-Tissue Expression (GTEx). We
hypothesized that the effects of the SNP genotypes on AD risk may reflect genotypes based
differences in levels of the gene expression in the brain. To investigate this, we analyzed
recently released GTEx Consortium data. In postmortem samples from 100–120 normal
individuals from the GTex dataset, among the disease associated SNPs, only rs4895829
genotype was associated with the expression level in the cerebellum (p = 7.3×10−5, Fig. 2),
with GG genotype carriers showing the lowest levels of expression as compared with GC
and CC genotypes (G is minor allele).
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4.

Discussion

Author Manuscript

In the present study, we examined the association of PTPRK gene with the risk and AAO of
AD by using a case-control dataset and a family based-study sample for replication. In the
case-control data, five SNPs were associated risk of AD and six SNPs were associated with
AAO. Using FBAT-GEE and FBAT-Wilcoxon statistics in the family sample, we found that
seven SNPs were significantly associated with the risk of AD and 12 SNPs were associated
with the AAO of AD in the family-based dataset; while one SNP (rs7748155) was associated
with both risk and AAO. There were few SNPs in the PTPRK gene that overlapped between
these two data sets, which may be due to different arrays used for genotyping. The findings
of the case-control design were confirmed by the results found using a family sample at the
gene level in our current study. We also demonstrated homozygous disease associated
genotype (GG) of rs4895825 displayed the lowest levels of expression as compared to other
genotype groups (CG and CC) in human cerebellum brain tissue (Fig.2). In addition, one
additional sample showed that several SNPs were associated with the risk of cancer and
cholesterol levels.

Author Manuscript

To the best of our knowledge, this is the first study to investigate the association of PTPRK
gene with AD, especially with AAO of AD. A previous study has identified the APOE e4
allele with AAO of AD (Williamson et al., 2009). However, APOE genotyping was neither
fully specific nor sensitive (Bird, 2008). Genetic factors for AAO play an important role in
the prevention and early treatment intervention of AD. A multi-gene approach will be
effective in the screening and prevention of AD. The PTPRK gene investigated in this study
is highly expressed in the human brain. Although the biological functions of PTPRK in
neoplastic cells are still poorly characterized, PTPRK mediates highly specific intercellular
homophilic interactions suggesting that it can directly sense cell-cell contact and thereby
mediate contact inhibition of cell growth (Yang et al., 1997). The PTPRK is known to be upregulated by transforming growth factor-beta (TGF-β), and therefore likely involved in
mediating TGF-β dependent anti-proliferative and cell migration effects (Wang et al., 2005).
Previous studies have already found that an overproduction of TGF-β can cause cerebral
amyloid angiopathy, which is frequently associated with AD (Wyss-Coray et al., 1997;
Ueberham et al., 2005). Other studies have also shown that several SNPs within PTPRK
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gene are associated with three adult psychiatric disorders: schizophrenia, major depressive
disorder and bipolar disorder (Hamshere et al., 2009; Network and Pathway Analysis
Subgroup of Psychiatric Genomics Consortium et al., 2015). In the present study, the ADassociated SNP rs17461290 and AAO-associated SNP rs10872331 were previously
associated with bipolar schizoaffective disorder (p=0.0165 and 0.049, respectively)
(Hamshere et al., 2009); while the AD-associated rs11753971 and AAO-associated
rs7767531 were previously associated with across three adult psychiatric disorders:
schizophrenia (p=0.024 and 0.0949, respectively), major depressive disorder (p=0.0204 and
0.0343, respectively) and bipolar disorder (p=0.0207 and 0.0579, respectively) (Network and
Pathway Analysis Subgroup of Psychiatric Genomics Consortium et al., 2015).
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In the present study, four SNPs (rs1339197, rs9491931, rs9402020 and rs7767531) were
associated with cancer; especially, the rs1339197 was also associated with AAO of AD in
the family-bases sample, which suggested that PTPRK may play a role in AD and cancer.
The PTPRK gene is involved in the processes related to many tumors, and the locus 6q22–
23 is a common region of allelic deletion at chromosome 6 in several cancers (Yang et al.,
1997). Previously, PTPRK as a potential tumor suppressor gene has been investigated by
many cancer researchers. Some of these cancers were associated with AD or had a high
prevalence in patients with AD in a number of studies. For example, Nakamura and his
colleague reported that PTPRK may be a putative tumor suppressor, and appear to be
relevant to the pathogenesis and prognosis of primary central nervous system lymphomas
(PCNSLs) (Nakamura et al., 2003). The PCNSLs were reported to be present in progressive
dementia that is a major form of AD (Burns and Iliffe, 2009). The study by Agarwal and
colleagues indicated that PTPRK is significantly relevant to glioma pathogenesis (Agarwal
et al., 2013). Furthermore, previous studies demonstrated that Alzheimer’s disease and
glioblastoma shared a yet unknown pathway that can promote the progression of both
diseases (Lehrer, 2010; Deutsch and Mendez, 2015). Another study suggested PTPRK was
the most likely candidate tumor suppressor gene for endocrine pancreatic tumors (Barghorn
et al., 2001). Recent studies also reported that PTPRK was a key factor in coordinating
apoptosis in prostate cancer cells (Sun et al., 2013). An epidemiological study which used
National Cancer Institute’s Surveillance, Epidemiology and End Results (SEER) Program
data showed the higher prevalence of pancreatic cancer and prostate cancer in patients with
AD than that in control subjects (Burke et al., 1994). Stevenson and colleagues’ study
suggested PTPRK-mediated cell signaling pathway may be targeted with epigenetic
therapies in acute lymphoblastic leukemia (Stevenson et al., 2014). Another study also found
a relationship between acute lymphoblastic leukemia and AD by an immunological method
(Sato et al., 1991). Therefore, the PTPRK gene may play a similar role in the progression of
these cancers and AD.
Previous studies demonstrate that cholesterol levels are associated with dementia related
(Ahmed et al., 2014; Giudetti et al., 2016). Our results further showed that 12 SNPs
associated with LDL-cholesterol and 8 SNPs associated with total cholesterol. Interestingly,
rs7767531 was associated with cancer, LDL-cholesterol and total cholesterol; while the
same SNP is also associated with AAO in the family sample. However, future study is
required to validate our current findings using more SNPs in the PRPRK genes and a large
sample.
J Psychiatr Res. Author manuscript; available in PMC 2018 October 20.
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Moreover, based on the results of the in Silico analysis, we found four SNPs (rs7748155,
rs17055612, rs17055719 and rs17828130) were located at the gene regulatory regions; while
rs7748155 was also located at species-conserved region suggesting potential functional
importance of the PTPRK gene. The cholesterol associated SNP rs17828130 was a coding
nonsynonymous SNP and was located at the gene regulatory region; while rs9372885 was
located at the gene regulatory region. In addition, individuals carrying minor allele (disease
associated G allele) of AD risk SNP, rs4895829, demonstrated having significantly lower
gene expression of the PTPRK as compared with non-carriers. Thus, the in Silico analysis
adds additional evidence of supporting PTPRK gene in association with AD phenotypes.
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There are several strengths of this study. First, we used population-based case control sample
for initial study and then a family-based sample for replication. The family-based design
provided a robust and powerful approach to identify a full range of disease susceptibility
variants and confirmation of the results of case-control study. Second, several AD and its
AAO associated SNPs (rs17461290, rs10872331, rs11753971, and rs7767531) were
previously associated with psychiatric disorders. Third, we conducted association studies of
PTPRK with cancer and cholesterol levels. In addition, we performed functional analyses.
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There are a number of limitations in this study. For example, the small number of SNPs of
the PTPRK gene in the GenADA sample led to a little overlap of the SNPs in the two
samples. Some disease and AAO associated SNPs in the PTPRK gene were different
between in the two sample sets indicating that phenotypic and genotypic heterogeneity exists
in AD and AAO. Therefore, our replication results in AD and its AAO are gene-based rather
than SNP-based. Furthermore, current findings might be spurious or subject to type I error.
Future confirmatory studies, or targeted genome sequencing the PTPRK gene in AAO of AD
in the current sample sets, may provide an opportunity to dissect the genetic complexity of
this gene in this disorder more accurately.

5.

Conclusion

Author Manuscript

We discovered a significant association between PTPRK genetic variants and the risk and
AAO of AD in two independent samples. To our knowledge, this finding of AD associated
PRPRK variants has not been previously reported. Furthermore, we provided initial evidence
of several genetic variants in PTPRK influencing the risk of cancer and cholesterol levels.
These results suggest a potential role of PTPRK in the pathogenesis of AD, cancer and
cholesterol metabolism. These findings may serve as a resource for replication in other
ethnic populations. In addition, future studies of this gene may help to characterize the
genetic function of AD risk and AAO and the biological pathway of pathogenesis and
prognosis of AD, cancer, and cholesterol levels.
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Figure.1.

The results of –log(p) values for single SNP analysis of risk and AAO of AD in the
GenADA sample.
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Figure 2.

Author Manuscript

Genotype at rs4895829 associates with gene expression in the brain and defines a clinically
important AD phenotype in eQTL Boxplot showing the association between rs4895829
genotype and gene expression in the cerebellum in 89 healthy postmortem samples (P =
0.000073) from the GTEx Consortium, with GG (Home Ref, N=4) genotype carriers
showing the lowest levels of expression. Medians and interquartile ranges are indicated. GC
genotype (Het, N=25) and CC genotype (Homo Alt, N=60) are shown.
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Table 1.

Author Manuscript

Descriptive characteristics of cases and controls.
Family Study (NIA sample)

Case-control study (Canadian sample)

Marshfield sample

AD Patients

Controls

AD Patients

Controls

Cancers

Controls

1266

1279

791

782

716

2848

Mean AAO (years±SD )

76.4±6.7

-

72.3±8.5

-

64.2±12.8

-

Range of age at onset (years)

50-98

-

40-97

-

40-97

-

Mean age at entry (years±SD)

-

75.5±8.1

77.6±8.6

73.4±7.9

71.1±10.3

65.1±11.3

Range of age at entry (years)

-

42-103

43-100

48-94

46-90

46-90

Variable
Sample size (n)

a

a

SD refers to the standard deviation of the mean.
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Table 2.

Author Manuscript

Single marker analysis of risk of AD and its AAO in the GenADA sample.

Author Manuscript

a

SNP

Position

a

AL

b

c
MAF

HWE

d

e
OR-AD

p-AD

f

β-AAO

g

p-AAO

rs4895829

128420786

G

0.17

0.145

0.65(0.47, 0.91)

0.0125

0.12(−0.34, 0.59)

0.6106

rs9375546

128417097

C

0.17

0.085

0.68(0.49, 0.93)

0.0151

0.16(−0.31, 0.61)

0.5168

rs4897243

128430767

T

0.17

0.132

0.68(0.49, 0.94)

0.0186

0.19(−0.27, 0.66)

0.419

rs2326681

128691100

C

0.01

0.843

2.11(1.01, 4.38)

0.0465

−1.86(−3.16, −0.56)

0.00518

rs17245411

128387064

C

0.05

0.532

0.69(0.48, 0.99)

0.0482

−0.22(−1.12, 0.67)

0.6238

rs1891150

128805122

C

0.03

0.397

0.86(0.56, 1.33)

0.5177

−2.19(−3.14, −1.23)

8.02E-06

rs1341597

128820851

T

0.03

0.452

0.93(0.60, 1.46)

0.7682

−1.97(−2.95, −0.99)

8.33E-05

rs17055598

128669758

A

0.01

0.759

1.53(0.78, 2.99)

0.2172

−1.81(−3.23, −0.38)

0.01324

rs1891149

128805026

A

0.06

0.775

1.17(0.86, 1.60)

0.313

−0.76(−1.43, −0.09)

0.02572

rs41514350

128527278

C

0.02

0.013

1.42(0.79, 2.55)

0.2392

1.27(0.03, 2.50)

0.0447

Physical position (bp);

b

Minor allele;

c

Minor allele frequency;

d

p-value for Hardy-Weinberg equilibrium test;

e

Odds ratio for AD;

f

p-value for AD;

g

Regression coefficient for AAO;

h

p-value for AAO.

Author Manuscript
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Table 3.

Author Manuscript

Single marker analysis of risk of AD based on FBAT-GEE (p<0.05).
SNP

a

a

b

c

d

e

f

p-FBAT-GEE

Position (bp)

AL

MAF

HWE

Fam#

rs1016015

128869961

T

0.01

>10−4

19

0.023(a) 0.023(d,r)

rs11753971

128614517

T

0.10

0.71

129

0.427(a) 0.0372(d,r)

rs11756545

128855588

C

0.09

0.63

146

0.0937(a) 0.0102(d,r)

rs17461290

128870929

T

0.16

0.96

194

0.265(a) 0.0332(d,r)

rs4341027

128348811

C

0.30

0.25

258

0.0504(a) 0.027(d,r)

rs7748155

128733046

C

0.19

0.19

183

0.696(a) 0.0157(d,r)

rs9398863

128362605

C

0.10

0.65

112

0.0233(a) 0.0611(d,r)

g

Physical position is based on NCBI Genome Build 36.3.

Author Manuscript

b

Minor allele.

c

Minor allele frequency.

d

p-value of Hardy-Weinberg equilibrium test.

e
f

The number of informative families using an additive model.

p-value based on FBAT-GEE analysis for affection status.

g

Letters in parentheses indicate the genetic models used for analysis (a, additive; d, dominant; r, recessive model).
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Table 4.

Author Manuscript

Single marker analysis of AAO based on FBAT-Wilcoxon (p<0.05).

Author Manuscript

a

a

b

c

d

e

f

SNP

Position (bp)

AL

MAF

HWE

Fam#

p-FBAT-Wilcoxon

rs10428737

128781777

A

0.10

0.03

63

0.024(a) 0.032(d,r)

rs11966128

128650841

G

0.08

0.72

62

0.000139(a) 0.000778(d,r)

rs1339197

128649904

T

0.46

0.03

219

0.0135(a) 0.0108(d,r)

rs17055612

128674033

C

0.08

0.74

62

0.00302(a) 0.00177(d,r)

rs17055628

128677748

C

0.07

0.96

62

0.00185(a) 0.00106(d,r)

rs17055719

128694187

G

0.07

1.00

60

0.00353(a) 0.0021(d,r)

rs17456385

128668324

T

0.07

0.87

58

0.00799(a) 0.00499(d,r)

rs3822945

128782080

A

0.29

0.01

161

0.095(a) 0.0442(d,r)

rs7748155

128733046

C

0.19

0.19

132

0.0488(a) 0.0207(d,r)

rs7767531

128535684

G

0.35

0.09

190

0.01(a) 0.0236(d,r)

rs7773248

128682710

G

0.08

0.97

63

0.000685(a) 0.000369(d,r)

rs9402035

128702994

T

0.11

0.31

73

0.0108(a) 0.00708(d,r)

g

Physical position is based on NCBI Genome Build 36.3.

b

Minor allele.

c

Minor allele frequency.

d

p-value of Hardy-Weinberg equilibrium test.

e
f

The number of informative families using an additive model.

p-values based on FBAT-Wilcoxon analysis for age at onset.

g

Author Manuscript

Letters in parentheses indicate the genetic models used for analysis (a, additive; d, dominant; r, recessive model).
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Table 5.

Author Manuscript

Associations between SNPs and cancer and cholesterol levels in the Marshfield sample.

Author Manuscript
a

SNP

Positiona

ALb

MAFc

HWEd

OR-Cancere

p-Cancerf

β-LDLg

p-LDLh

β-Choli

p-Cholj

rs1339197

128649904

T

0.441

0.75

0.84(0.74, 0.95)

0.0041

1.38(−0.13, 2.89)

0.07436

1.10(−0.36, 2.56)

0.14

rs9491931

128614570

C

0.246

0.648

1.19(1.03, 1.36)

0.0157

−0.64(−2.42, 1.13)

0.4757

−0.89(−2.59, 0.81)

0.306

rs9402020

128505339

G

0.051

0.042

0.71(0.53, 0.95)

0.0229

2.14(−1.25, 5.53)

0.216

1.19(−2.02, 4.42)

0.469

rs7767531

128535684

G

0.334

0.018

0.87(0.76, 0.99)

0.0412

1.81(0.15, 3.48)

0.0326

1.99(0.40, 3.59)

0.01402

rs4544930

128436582

T

0.204

0.016

0.97(0.83, 1.13)

0.677

−2.86(−4.77,−0.94)

0.00347

−2.30 (−4.14, 0.47)

0.014

rs1012049

128572000

A

0.275

0.417

0.92(0.80, 1.06)

0.236

2.41(0.72,4.100

0.00531

2.28(0.65, 3.91)

0.00609

rs9372885

128517784

T

0.021

0.313

0.68(0.43, 1.08)

0.0991

6.84(1.91,11.8)

0.0066

4.63(−0.17, 9.43)

0.0588

rs3813372

128555088

G

0.016

0.446

0.65(0.37, 1.12)

0.118

7.81(1.74,13.9)

0.0118

4.85(−0.93,10.6)

0.1

rs9402030

128602695

G

0.015

0.488

0.55(0.29, 1.02)

0.0557

8.39(1.82,14.9)

0.0124

5.70(00.55, 12.03)

0.0739

rs9372887

128607471

A

0.013

0.531

0.59(0.32, 1.12)

0.107

8.01(1.20,14.8)

0.0213

5.71(−0.75, 12.17)

0.0834

rs6912749

128438700

T

0.229

0.033

0.98(0.85, 1.13)

0.767

−2.03(−3.85, −0.19)

0.0301

−1.56(−3.32, 0.20)

0.0829

rs12528715

128588870

G

0.049

0.019

1.16(0.90, 1.51)

0.258

3.61(0.27, 6.94)

0.0342

2.55(−0.69, 5.79)

0.123

rs17055441

128573344

A

0.017

0.436

0.63(0.36, 1.09)

0.095

6.60(0.43, 12.7)

0.0362

4.52(−1.34, 10.4)

0.131

rs13213933

128590678

A

0.049

0.019

1.17(0.90, 1.52)

0.241

3.53(0.19, 6.88)

0.0383

2.57(−0.68, 5.83)

0.121

rs17352289

128656785

A

0.072

0.184

0.87(0.69, 1.10)

0.252

2.90(0.08,5.73)

0.0439

3.69(0.93,6.44)

0.00887

rs9398869

128783169

A

0.082

0.218

1.08(0.87, 1.33)

0.505

2.21(−0.42,4.84)

0.1

3.28(0.68, 5.88)

0.0134

rs17828130

128445438

A

0.365

0.024

0.90(0.80, 1.03)

0.117

1.57(−0.02, 3.16)

0.0535

1.70(0.18, 3.22)

0.0283

rs6914064

128824612

C

0.421

0.497

0.99(0.88,1.12)

0.871

0.94(−0.59,2.47)

0.23

1.49(0.28, 2.94)

0.0458

Physical position (bp);

b

Minor allele;

c

Minor allele frequency;

Author Manuscript

d

p-value for Hardy-Weinberg equilibrium test;

e

Odds ratio for cancer based on logistic regression;

f

p-value for canccer based on logistic regression;

g

Regression coefficient for LDL based on linear regression;

h

p-value for LDL based on linear regression;

i

Regression coefficient for total cholesterol level based on linear regression;

f
p-value for total cholesterol level based on linear regression.

Author Manuscript
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